Detalles de la búsqueda
1.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet;
396(10267): 1994-2005, 2021 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33308425
2.
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Br J Clin Pharmacol;
88(10): 4607-4622, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35695476
3.
Test of cure study: a feasibility study to estimate the time to test of cure (TOC) for Neisseria gonorrhoeae and Chlamydia trachomatis infections.
Sex Transm Infect;
96(6): 402-407, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32447324
4.
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
J Antimicrob Chemother;
72(6): 1760-1768, 2017 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28369381
5.
Trypanosoma cruzi screening in people living with HIV in the UK.
Int J STD AIDS;
35(1): 71-73, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37728103
6.
A phase I, first-in-human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937.
Pharmacol Res Perspect;
11(3): e01093, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37269076
7.
Evaluation of PIMA point-of-care CD4 testing in a large UK HIV service.
Sex Transm Infect;
88(6): 413-7, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22544309
8.
Multicentre RCT and economic evaluation of a psychological intervention together with a leaflet to reduce risk behaviour amongst men who have sex with men (MSM) prescribed post-exposure prophylaxis for HIV following sexual exposure (PEPSE): a protocol.
BMC Infect Dis;
12: 70, 2012 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-22440090
9.
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
J Acquir Immune Defic Syndr;
91(2): 157-161, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36094481
10.
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
AIDS;
36(2): 185-194, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34261093
11.
Is the recall of men who have sex with men (MSM) diagnosed as having bacterial sexually transmitted infections (STIs) for re-screening a feasible and effective strategy?
Sex Transm Infect;
87(7): 577-82, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21965470
12.
Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimens.
Int J STD AIDS;
32(12): 1165-1173, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34156330
13.
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Patient;
14(6): 849-862, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34056699
14.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet HIV;
8(11): e679-e689, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34648734
15.
Pooled specimens for HIV RNA monitoring: cheaper, but is it reliable?
Clin Infect Dis;
59(9): 1346-7, 2014 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25034422
16.
Does using self-completed sexual history questionnaires in HIV-positive men who have sex with men affect clinical outcomes?
Int J STD AIDS;
19(3): 203-5, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18397564
17.
UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposure.
Int J STD AIDS;
17(2): 81-92, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16464267
18.
Current perspectives in HIV post-exposure prophylaxis.
HIV AIDS (Auckl);
6: 147-58, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25368534
19.
Prevalence of vitamin D deficiency in HIV-positive, antiretroviral treatment-naïve patients in a single centre study.
Int J STD AIDS;
25(7): 488-92, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24352123
20.
HIV and postexposure prophylaxis.
Clin Med (Lond);
8(3): 319-22, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18624047